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Abstract
Schizophrenia is a serious mental disorder characteristic of several neurotransmitters
including dopamine, serotonin, and glutamate being in imbalance. Early therapies focused solely
on dopamine antagonism and second-generation antipsychotics focused on the dopamine and
serotonin systems and their respective G protein coupled receptor (GPCR) proteins. Although
debate for dimerization of certain classes of GPCR exist, the establishment of an mGlu2-5-HT 2A
heterocomplex, which is implicated in schizophrenia is of interest. Previous studies have used a
mutation-based approach to identify transmembrane domain 4 (TM4) as the domain responsible
in mGlu2 for mediating heteromerization before narrowing down the individual amino acids
responsible for the interface. A similar approach to consider which portion of 5-HT 2A is
responsible for the heterodimeric interface was used in this study. We confirm that wild type 5HT2A and mGlu2 coimmunoprecipitate. Two 5-HT2A chimeric constructs involving full and
partial N terminal half TM4 mutations were created using aligned residues of 5-HT 2C (which is
unable to dimerize with mGlu2). In addition to providing valuable insight into the structural
arrangement of GPCR heteromers involving different families, these findings offer future
direction for photo-crosslinking experiments aiming to identify individual amino acids within the
5-HT2A responsible for mediating the heteromeric interface of the mGlu2-5-HT 2A complex.
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Introduction
Schizophrenia
Schizophrenia is a debilitating and deteriorating mental disorder that affects roughly 1%
of the world population (Saha, 2005). Schizophrenic patients report a combination of positive,
psychotic symptoms including hallucinations and delusions in addition to several neurocognitive
deficiencies (generally attributed as the negative and cognitive symptoms of schizophrenia.)
These symptoms are outlined in the table below and there are key differences in the distribution
of positive, negative, and cognitive symptoms when comparing schizophrenia patients to those of
affective psychosis such as bipolar disorder and psychotic depression (Saha, 2007). While some
schizophrenic subjects are more aware than others that their positive psychotic symptoms cannot
be a manifestation of reality, the persistent hallucinations and delusions remain a relentless issue
for the patient which can affect their ability to socially integrate in society; patients may also
experience impaired judgment due to these positive effects; for example, a schizophrenic patient
acting upon an auditory hallucination which he/she perceived to have heard, despite its absence
in reality.
Table of Positive, Negative, and Cognitive Symptoms in Schizophrenia
Positive Effects

Negative Effects

Cognitive Effects

Hallucinations

Speech Poverty (Alogia)

Attention deficit

Delusions

Lack of emotion / interest

Verbal, Visual, and

/Asociality

Working Memory deficit

Apathy or Inexpression

Executive Function
(Reasoning) deficit

Anhedonia

Social Cognition deficit

Table 1. List of Positive (Psychotic), Negative, and Cognitive effects of Schizophrenia
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Although the more commonly mentioned symptoms of schizophrenia tend to be positive
or psychotic in nature, the negative and cognitive effects of the disease can be equally
debilitating. Negative symptoms, as implied in the name, represent an absence or reduction, for
example, in speech (alogia). Anhedonia – an inability to feel pleasure – and blunted affect,
characterized by reduced general expression, are also considered to be negative schizophrenic
symptoms (Andreasen, 1982.) The cognitive symptoms of schizophrenia, as outlined by the
MATRIX (Measurement and Treatment Research in Cognition in Schizophrenia) project,
adversely affect “speed of processing, sustained attention, working memory, verbal learning,
visual learning, executive function, and social cognition” (Nuechterlein, 2004). The cognitive
changes associated with schizophrenia may present earlier than symptoms of psychosis and last
the duration of the patient’s lifetime (Ibrahim, 2012).
Positive symptoms can be treated with typical and atypical antipsychotics as detailed later
in the text. Many antipsychotic drugs do not eliminate the negative or cognitive symptoms of
schizophrenia; however, these symptoms are often the reason schizophrenics patients have
difficulty participating in society (for example: cognitive dysfunction resulting in inability to live
independently, ineptitude in social situations making it tough to maintain relationships; lack of
motivation/interest leading to diminished quality of life in general (Miyamoto, 2012).
The life span of an average schizophrenic subject is usually 15 years shorter than the
general population, indicating additional costs associated with the disease that expand beyond
the positive and negative symptoms described above (Saha et al., 2007). The risk of morbidity is
further exaggerated in schizophrenic patients displaying conditions such as respiratory and
cardiovascular disease (Olfson, 2015). As with many mental disorders the risk of suicide is
2

increased and studies estimate that patients experience a lifetime risk of suicide around 5-10%
(Hor, 2010; Freedman 2003), this risk, although still present, can be exponentially lowered with
treatment, particularly with atypical antipsychotic clozapine, detailed later in this paper (Meltzer,
2013). Most patients experience an onset of the disease between ages 15-35 (Kurita et al., 2016).
Given the nature of the disease, it becomes apparent that schizophrenia is a mentally and
physically debilitating condition with costs reaching beyond the initial symptoms displayed by
patients.
Dopamine in Schizophrenia and the Emergence of Typical Antipsychotics
Schizophrenic symptoms are generally attributed to dysfunction in dopamine
neurotransmission in the brain. Dysregulation of the dopamine circuit may present itself in
schizophrenic patients as an overstimulated mesolimbic dopamine pathway with a concurrent
lack of dopamine activity in the mesocortical pathway (Davis et al., 1991). The positive
symptoms of schizophrenia are associated with the hyper stimulation of neuronal projections on
D2 receptors in the mesolimbic pathway. On the other hand, dopamine D1 receptors experience
hypo-stimulation due to mesocortical projections to the prefrontal cortex being less active
(Guillin, 2007).
These alterations produced by schizophrenia can affect the activity of pyramidal neurons
in the prefrontal cortex, which serve roles in information processing, but also in the interneuron,
which plays key regulatory roles in neurotransmitter release by acting on pyramidal cells.
(Freedman, 2003.) The general function between these types of cells is shown to be disrupted by
evidence suggesting that the density of synaptic connections between neurons and interneurons is
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reduced. Activity between neurons and interneurons can be modulated by dopamine afferents but
also by serotonergic, cholinergic, and noradrenergic cortical afferents (Freedman, 2003).
Before exploring these other neurotransmitters systems, a discussion of the first
generational class of antipsychotic drugs focused on the dopamine system, is necessary.
Specifically, the first antipsychotics focused on dopamine receptor antagonism due to the
establishment of hyperexcitation in dopamine pathways leading to positive psychotic symptoms.
This class of antipsychotics were known as first generational antipsychotic drugs and include
haloperidol and perphenazine. While effective in mediating antipsychotic effects through D2
receptor blockade, this generation of antipsychotic drugs presented patients with side effects
such as weight gain, temperature dysregulation, and most notably, extrapyramidal side effects
(EPS) at clinically effective doses (Leucht, 2009). These EPS effects can be compared to the
tremors and bradykinesia experienced by Parkinson’s patients and result in overall reduction of
motor function. A distinction between typical and atypical antipsychotics can be made by the
absence of EPS in atypical antipsychotics (discussed further below); for this reason, many first
generation APDs are classified as typical. Although, typical APDs seemed to be somewhat
effective in alleviating positive symptoms, the presence of EPS symptoms and consideration of
targets other than dopamine receptors encouraged research of a second generation of
antipsychotic drugs.
Serotonin in Schizophrenia and the Emergence of Atypical Antipsychotics
As mentioned above, many other neurotransmitter systems are implicated in
schizophrenia in addition to dopamine dysregulation. Unlike first generational APDs which were
often supplemented by anti-parkinsonian drugs to limit their extrapyramidal side effects, patients
4

using second generation APDs reported fewer EPS symptoms. Clozapine was the first such drug
developed (Meltzer, 2012), and its therapeutic effects were achieved by a combination of
dopamine D1 and D2 antagonism coupled with 5-HT2A antagonism.
Clozapine and other second generational APDs developed after it are generally
considered atypical since they do not induce the EPS motor disturbances associated with
administration of typical first generational APDs; however, there is some variation in the exact
classification of typical and atypical APDs (Meltzer, 2013). Other atypical drugs which inhibit
both D2 and 5-HT2A receptors, in a manner similar to clozapine include risperidone and
quetiapine (Tran et al., 1997; Small et al., 1997). Later atypical psychotics acting as full or
partial agonists and antagonist in dopamine and serotonin receptors were also developed; this
includes amisulpride (strong 5-HT7 antagonist) and cariprazine (partial 5-HT2B/5-HT1A
antagonist/agonist). All of these drugs are characteristic of positive symptom suppression.
In terms of efficacy, clozapine was shown to decrease positive psychotic symptoms with
exceptional efficacy in patients displaying Treatment Resistant Schizophrenia (TRS) which
accounts for roughly 30% of all schizophrenic patients (Meltzer, 1997); a patient is considered to
have TRS following two or more unsuccessful treatments with other APDs. Although it is not
clear whether atypical antipsychotics are superior to typical antipsychotics in terms of efficacy in
non TRS patients, the presence of motor side effects (possibly resulting in the need to take
additional drugs to limit these effects) in typical APDs may be a key factor in selecting atypical
drugs over typical APDs.
The focus of many early antipsychotics in regulating solely dopamine receptor activity
before the later development of multitargeted atypical antipsychotics to provide simultaneous
5

dopaminergic and serotonergic inhibition begs a question: what other neurotransmitters or
receptors can be considered in the characterization of schizophrenia in addition to dopamine,
serotonin, and their respective receptors? To assess this, we begin by considering psychedelics,
which are intimately involved with the serotonin receptor 5-HT 2A.
General GPCR characteristics and Psychedelics as a Model of Schizophrenia
Psychedelic compounds can produce altered perception and distort feeling and include
the compounds LSD (lysergic acid diethylamide) and psilocybin (C 12H17N2O4P) (Hanks, 2016).
LSD was first discovered by Dr. Albert Hoffman in 1943 after which the structural similarities
between serotonin and LSD were examined more closely, and psychedelic substances were
ultimately categorized as 5-HT2A serotonin receptor agonists. Psychedelic substances induce
feelings like those of positive schizophrenic symptoms (Hanks, 2016). Due to this, psychedelics
have been used in numerous animal models of schizophrenia in which psychedelic agonists, but
not non-psychedelic 5-HT2A agonists, produce a head twitch response, a behavior analogous to
positive hallucinogenic symptoms, in rodents (González-Maeso, 2007). The head twitch
movements are not found in knockout mice missing the 5-HT 2A receptor (González-Maeso,
2007); thus, suggesting that the psychedelic effect of LSD and other psychedelics such as
psilocybin is mediated by 5-HT2A agonist activity.
The affinity of psychedelic compounds to GPCRs such as 5-HT 2A is of interest as the
serotonin receptor, particularly the 5-HT2A, is a target of atypical antipsychotics, such as
clozapine detailed above. Since dopamine D1 and D2 receptors as well as the 5-HT 2A receptor
fall under the classification of GPCRs, the general structure and functional basis of GPCRs
should be considered.
6

Serotonin (5-HT), Dopamine (D1/2), and metabotropic Glutamate (mGlu2/3) receptors
(detailed below) fall under the family of GPCRs of which over 800 different types were
identified in the human genome (Davenport, 2013). GPCRs contain 7 conserved heptahelical
transmembrane domains connected by intracellular and extracellular loop residues; an
extracellular N terminus and intracellular C terminus is also characterized by sites for
extracellular ligand binding and glycosylation, and intracellular phosphorylation (GonzalezMaeso, 2006). As the name suggests, GPCRs allow for intracellular signaling cascades in which
ligand binding allows for activation of attached G protein; more specifically the alpha subunit of
the GPCR dissociates from the beta/gamma subunits and allow the subunits to regulate
respective effectors. The adopted schematic below from Principles of Endocrinology and
Hormone Action, 2018 shows the general features of a GPCR mentioned above.
Schematic adopted from: Principles of Endocrinology
and Hormone Action
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Depending on the type of G protein, a signaling cascade involving activation of second
messengers such as cAMP, calcium, and protein kinases can be detected (Pincas et al., 2018).
For example, the 5-HT2A receptor is Gq/11-coupled resulting in Inositol trisphosphate and
diacylglycerol (IP3/DAG) mediated calcium release from the endoplasmic reticulum upon
receptor activation. The metabotropic glutamate receptor, discussed later in the paper, utilizes
Gi/o-coupled signaling, characteristic of inhibiting adenylyl cyclase, and thus downstream cAMP
production (Gonzalez-Maeso, 2011.) The dopamine D2 receptor is also G i/o-coupled while the
D1 receptor is Gs/olf-coupled and has essentially the opposite effect: activation of adenylyl
cyclase and activation of cAMP (Gurevich, 2016). Finally, G11/12-coupled GPCRs activate the
Rho family of GTPases and serve functions primarily in cytoskeletal remodeling and migration
of fibroblast and endothelial cells (Dhanasekaran, 1996; Shan 2006).
GPCRs were originally separated into 3 major classes based on structure: class A
rhodopsin like receptors, class B secretin family receptor, and class C metabotropic glutamate
receptors. However, adhesion class and frizzled class GPCRs can also be considered for a total
of 5 families (Lee et al. 2015). There is no shared sequence homology among the different
classes of GPCR; the greatest homology usually occurs in the cores of transmembrane domains
of GPCRs within the same family. GPCRs contain orthostatic sites for endogenous ligand
binding but also contain allosteric sites which do not bind ligand; rather they bind to Positive
(PAMS) or Negative Allosteric Modifiers (NAMS) which can modulate response to an
orthostatic agent (ligand) binding - the existence of several potential targets present in GPCRs
may explain why almost 35% of FDA approved drugs target GPCRs (Foster & Conn, 2017;
Hauser, 2018).
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Classically, GPCRs were considered functional monomeric entities; this was based on
evidence that purified monomeric family A GPCRs such as β2-adrenoreceptor, Rhodopsin, and
the μ-opiate receptor reconstituted in a phospholipid bilayer, were sufficient for activation
(Whorton, 2007; Whorton, 2008; Kuszak, 2009). However, later evidence reported with regard
to dopamine D2 receptors, that a minimal signaling unit of 2 receptors and one protein can cause
activation, suggesting that class A receptors may homodimerize (Han et al., 2009). The
asymmetrical interface of the D2 protomers seemed to modulate each other upon agonist and
inverse agonist binding further supporting the case for GPCR dimerization. The topic of Class A
GPCR dimerization is still debated today; however, other GPCRs such as class C metabotropic
Glutamate (mGlu) and GABAB receptors have been reported to act as obligate dimers. For
example, the mGlu family homodimers are linked covalently through disulfide bridges
connecting their N-terminal Venus fly trap domain (Niswender, 2010.)
Studies involving the GABAB (γ-aminobutyric acid type B) receptor also shed light on
GPCR dimerization, specifically heterodimerization. GABA is the main inhibitory
neurotransmitter acting though GABAB receptors; the original gene for the receptor, GABAB-R1
was cloned in 1997 but the receptor was not expressed in cell lines. However, one year later, the
GABAB-R2 subtype was shown to form a heteromeric complex with GABA B-R1 as shown in
several studies (Jones, 1998, White, 1998; Kaupmann 1998.) Alone, neither protomer can both
bind ligand and activate the G protein, but co-expression of both the GABA B-R1and GABAB-R2
lead to a fully functional GABAB receptor (Jones, 1998, White, 1998; Kaupmann 1998).
Dimerization involving GPCRs of distinct subtypes/families include the κ and δ opiate
receptors in which the protomers have been shown to heteromerize and modulate each other
9

(Jordan, 1999). Another such heteromeric complex including distinct families of GPCRs and is
of especial interest in schizophrenia is the mGlu2/5-HT2A heteromeric complex.
The mGlu2/5-HT2A Heteromeric Receptor Complex
As mentioned previously, psychedelics such as LSD can stimulate the 5-HT 2A receptor
resulting in psychosis like behavior, which can be behaviorally quantified in animal models.
Recall that 5-HT antagonism is a mechanism of many second generational atypical antipsychotic
drugs; thus, a GPCR containing 5-HT2A complexed with a glutamate receptor (glutamate is a
main excitatory neurotransmitter in the brain) is of interest when considering therapeutic drugs
for schizophrenia. Additionally, mGlu2/3 has been a target for some therapeutic agonists such as
LY2140023 which have shown improvement in the positive and negative symptoms of
schizophrenia (Patil, 2007) However, other mGlu2/3 agonists such as LY379268 require 5-HT 2A
expression inducing head twitch behavior in order to provide antipsychotic action in mice
(Moreno, 2011; Hideshima, 2018).
Although initial postmortem brain studies of schizophrenic patients reported mixed
results regarding the density of serotonin receptors, a 2008 study using binding assays found that
cortical membranes of untreated schizophrenic patients had increased densities of 5-HT 2A
receptors with concurrent decreases in mGlu2/3 levels. This increase in 5-HT 2A receptor density
was not found in postpartum brains of patients treated with clozapine, which was attributed to
chronic antipsychotic administration downregulating levels of 5-HT 2A (Gonzalez-Maeso, 2008).
Furthermore, the mouse studies found that “the mGluR2 component of the [mglu2/5-HT 2A]
complex eliminates the hallucinogen-specific component of the signaling in response to LSD-
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like drug; [thus this pattern of 5-HT2A and mGlu2 density may predispose schizophrenia.]”
(Gonzalez-Maeso, 2008.)
Functional cross talk has also been established between the two protomers of the 5-HT 2AmGlu2 complex and is of relevance to schizophrenia. Recall the several pathways by which
GPCRs can conduct a signal – the 5-HT2A receptor is Gq/11 coupled while the mGlu2 receptor is
Gi/o-coupled. In general, the Gi/o coupled pathways inhibit the production of adenylyl cyclase
while Gq/11 pathways lead to an increase in calcium release mediated by IP3/DAG. The existence
of multiple signal transduction pathways in the heterodimer allows for assessment of the
downstream interactions induced by either protomer. For example, researchers found that when
the 5-HT2A-mGlu2 complex was stimulated with LY379268, an mGlu2 agonist, there was also
activation of Gq/11 proteins by the 5-HT2A portion of the complex; this did not occur in 5-HT2A
deficient mice (Moreno, 2016).
Further studies on the mGlu2/5-HT2A heteromeric complex, suggest that
in response to endogenous ligands glutamate and serotonin, the mGlu2/5-HT 2A heteromer
establishes a Gi/o-Gq/11 balance which may result in behavioral responses different from 5-HT 2A
and mGlu2 homomers (Fribourg, 2011). In summary, the assembly of the heteromeric complex
reduces 5-HT mediated Gq/11 signaling and increases mGlu2 mediated Gi/o signaling. There is a
Gi/o-Gq/11 imbalance in psychosis that can be modulated by 5-HT2A and mGlu2 agonists or
inverse agonists. For example, 5-HT agonists and mGlu2 antagonists shift the G i/o-Gq/11 balance
to those more similar to psychotic conditions than physiological conditions. Likewise, mGlu2
agonists and 5-HT inverse agonists would accelerate Gi/o signaling while diminishing Gq/11
signaling – shifting the balance towards physiological conditions. See adopted schematic:
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Schematic adopted from: Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.

In a condition as complicated as schizophrenia, with several interconnected brain
pathways being in balance with one another, there is a need for drugs that are multi-targeted. The
transition from typical to atypical antipsychotic drugs shows the importance of considering
additional protein targets involved in schizophrenia. The 5-HT 2A-mGlu2 receptor complex is a
prime example of such targets.
Mutational Approaches to Map the Heteromeric Interface of 5-HT2A-mGlu2
Several studies have taken a mutation-based approach to assess the hetero-dimeric
interface of the mGlu2-5-HT2A complex. A study using immunocytochemistry verified the
colocalization of 5-HT2A and mGlu2 in tissue. These studies shed light on the phenomena that
mGlu2 but not mGlu3 colocalizes in cortical tissue and in cell culture (Gonzalez-Maeso, 2008.)
A similar discrimination between 5-HT2A and 5-HT2C (in which only 5-HT2A but not 5-HT2C can
dimerize with mGlu2) is used to assess the aims of my study.
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Specifically, previous studies have demonstrated the importance of TM4 in mGlu2 in
mediating the heteromeric interface of the mGlu2-5-HT 2A heterocomplex (Moreno, 2012). This
study, in which residues of mGlu3 are swapped into mGlu2 at the predicted sites within the
heteromeric interface, was assessed by coimmunoprecipitation to see if the interface could be
broken. By this method, researchers were able to identify TM4 but not TM5 of mGlu2 as
necessary for 5-HT2A-mGlu2 heteromerization (Moreno, 2012). Furthermore, the researchers
created mutant mGlu3 chimeras with a TM4 domain from mGlu2 and found upon
immunoprecipitation that TM4 of mGlu2 was also sufficient for mediating the heteromeric
interface. (Moreno, 2012)
A follow up study also implicated TM4 of 5-HT 2A to be involved in mediating the
heteromeric interface of the mGlu2-5-HT2A. This study first confirmed that WT 5-HT2A but not
WT 5-HT2C coimmunoprecipitated with mGlu2 and could form a complex (Moreno, 2016.) As
mentioned earlier, this relationship between 5-HT 2A and 5-HT2C is analogous to that of mGlu2
and mGlu3. The mutant chimeras created in my thesis experiments included aligned residues
from TM4 of 5-HT2C within portions of the TM4 of 5-HT2A in attempt to disrupt the binding
interface of the heteromer.
After Identifying TM4 of mGlu2 as the domain responsible for mediating
heteromerization. Researchers identified Ala-6774.40, Ala-6814.44, and Ala-6854.48 as the
individual amino acids responsible for the heteromeric interface in mGlu2 (Moreno 2012). The
numbering system used to describe the residues above follows the Ballesteros-Weinstein
numbering system for conserved GPCR residues (Ballesteros, 1995); in this system, the most
conserved residue across species, R, within a given transmembrane domain, X, is denoted as
13

RX.50. All residues adjacent to RX.50 towards the N terminus are given sequentially decreasing
numbers (RX.49, RX.48, etc,) while those towards the C terminus are given sequentially increasing
numbers relative to RX.50). Since the Moreno, 2012 experiment was concerned with residues in
TM4 of mGlu2, we see the corresponding Ballesteros-Weinstein numbering used. The findings
of the paper were based on substitutions at these positions resulting in the abolishment of
hallucinogenic behavior. A follow up study, with an emphasis on identifying a direct interaction
between these residues and the heteromeric interface, utilized amber codon suppression to
introduce photoreactive unnatural amino acid azF (p-azido-L-phenylalanine) at these sites along
the intracellular end of TM4; they concluded that Ala-677 4.40, Ala-6814.44, and Ala-6854.48 of
mGlu2 are directly involved in mediating the heteromeric interface (Maeso Group, unpublished).
While this thesis is primarily focused on identifying halves of the transmembrane
domain responsible for heteromerization rather than individual amino acids, the greater goal of
this project is to eventually identify the individual residues of 5-HT 2A responsible for mediating
the heteromeric interface by following a similar approach taken with mGlu2.
Coimmunoprecipitation studies can identify whether portions of 5-HT 2A TM4 are involved in
heteromerization but a coimmunoprecipitation assay cannot establish a direct interaction between
amino acids. Several approaches, however, have described the use of photoreactive unnatural
amino acids in GPCRs to cross link individual residues in close proximity with one another; such
studies have been conducted in the CXCR4 GPCR implicated in HIV, and the neurokinin-1
(NK1) family A GPCR (Grunbeck, 2011; Valentin-Hansen, 2014). The general method for this
approach involves co-transfection of a “cocktail” of plasmids – a synthetase gene, a suppressor
tRNA gene, and a gene encoding the GPCR to introduce an unnatural amino acid (UAA) at a site
of interest, such as azF; when excited by ultraviolet light, azF can form chemical cross links with
14

a sensitivity of 3-5 angstroms; indicating the presence or lack of a direct interaction by the
residues mutated (Huber, 2014). The mutant constructs created in this thesis, and the
interpretation of their Co-IP results, can be used as a starting point in identifying individual
amino acids by the photo-crosslinking methods described above, if found to be implicated in
mediating the heteromeric interface of the mGlu2-5HT 2A complex.
The dysregulation of several neurotransmitter systems in schizophrenia warrants closer
consideration of the GPCRs involved in each pathway. The limitations of early antipsychotics
focused primarily on dopamine receptors to alleviate the positive symptoms of schizophrenia
were addressed by assessing the roles of other GPCRs such as 5-HT 2A in the production of
atypical antipsychotics. The benefit of such exploration demands consideration of additional
proteins and protein complexes implicated in schizophrenia, such as the 5-HT 2A-mGlu2. We
consider a mutation-based approach to identify which portion of the 5-HT 2A is involved in
mediating the heteromeric complex.

15

Objectives
Due to the biological relevance of GPCRS in neuropsychiatric disorders generally, and
keeping in mind the changes in receptor density, particularly of the mGlu2 and 5-HT 2A GPCRs
in schizophrenia and their colocalization, this study aims to identify a portion of TM4 of the 5HT2A responsible for mediating the heteromeric interface within the mGlu2-5-HT 2A complex.
The implication of transmembrane domain four (TM4) within the 5-HT 2A receptor in
mediating heteromerization of the mGlu2-5-HT 2A complex allows deeper investigation into the
residues contained within it. It also begs a question: which half of the transmembrane domain
may contain the residues responsible for the interface. With this in mind, my Masters research
aims to identify whether the residues in the N terminal half of TM4 of 5-HT 2A are involved in
heteromeric complex formation. Because research has established that TM4 of 5-HT 2A is
necessary to form the mGlu2-5-HT2A complex (Moreno et al 2016), the study aims to ultimately
identify residues within the TM4 of 5-HT2A that are necessary to form the mGlu2-5-HT2A
complex. To do this, I substituted residues in half of the TM4 of 5-HT 2A closest to the N
terminus, with aligned residues in 5-HT2C to create 2 constructs. One of these constructs is
considered partially mutated (5-HT2A-TM4ΔNP) while the other is considered a full mutation of
half the TM4 residues lying closest to the N terminus (5-HT 2A-TM4ΔNF). Essentially, the 5HT2A-TM4ΔNP (partial) chimera contains swapped 5-HT 2C residues spanning a quarter length of
the TM4 closest to the N terminus, while the 5-HT 2A-TM4ΔNF (full) construct is mutated to
include residues from 5-HT2C along the entire half of the TM4 of 5-HT2A closest to the N
terminus. All three constructs, (WT 5-HT2A, 5-HT2A-TM4ΔNP, 5-HT2A-TM4ΔNF) were
transfected individually or co-transfected with mGlu2 and prepared into membranes before
16

running a co-immunoprecipitation experiment and subsequent western blot to test whether
complex formation is disrupted. If the N terminal half of TM4 does indeed include residues
responsible for mediating complex formation, we would expect a stronger Co-IP signal from the
sample containing WT mGlu2 & 5-HT2A than compared to one containing co-transfection of
mGlu2 & the Mutant 5-HT2A-TM4ΔNF or 5-HT2A-TM4ΔNP. Furthermore, we would expect the
lack of a band (or at least a less intense band) in the coimmunoprecipitation of mGlu2 and any
mutant chimera originally containing the residues responsible for mediating the heteromeric
interface. This information would be extremely valuable in future studies pertaining to the
greater goals of this project; the possibility of using photo-crosslinked unnatural amino acids
would allow identification of individual 5HT2A residues directly interacting with the heteromeric
interface of the mGlu2-5HT2A heteromeric complex.
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Materials & Methods
Wild Type Plasmid Preparation
The constructs pcDNA3.1-c-Myc-5-HT2A-mCherry and pcDNA3.1-HA-mGluR2mCitrine, described previously in Moreno et al., 2016, were obtained. In brief, the WT
metabotropic glutamate receptor was tagged N terminally with hemagglutinin (HA) and Cterminally by mCitrine (a type of yellow florescent protein.) The WT serotonin receptor 5-HT 2A,
alternatively, is N-terminally tagged by c-Myc and C-terminally tagged with mCherry (a type of
monomeric red florescent protein.) All mutant 5-HT receptor chimeras include the same tags
described. Tagging receptor constructs allows for use of antibodies specific to the tag – and thus
the construct – during immunoblot and immunoprecipitation assays. Plasmids were purified and
amplified by methods detailed below.
Chimeric Human 5-HT2A Constructs with half of TM4 near N terminus Mutated with
residues of 5-HT2C: partial (5-HT2A-TM4ΔNP) and full (5-HT2A-TM4ΔNF)
In accordance with manufacturer instruction, QuickChange II site-directed mutagenesis
kit (Stratagene) was used to modify the primary structure of the Human 5-HT 2A receptor into full
and partial chimeric constructs containing residues of 5-HT 2C in the N terminal half of TM4. The
protocol involves the designing of primers before adding them to template DNA and cycling
temperatures to induce the mutations desired. For the partial mutant 5-HT 2A-TM4ΔNP, the
following forward and reverse primer were designed (duplex forming nucleotides highlighted):
Forward: 5'18

ATGGTCCAAACAGCAATGATTTTCATGATTGCCTTAGTTCTGGAGTTGAAGC-3'.
Reverse: 5'GCTTCAACTCCAGAACTAAGGCAATCATGAAAATCATTGCTGTTTGGACCAT-3'
The primers along with appropriate manufacturer included buffers and template c-myc-5HT2A- m-cherry (WT) construct DNA were Thermo-cycled with the following parameters: 1
cycle at 95°C followed by 16 cycles of 30 minutes at 95°C, 1 minute at 55°C and 8 minutes at
68°C. Following this, a restriction enzyme Dpn1 was used for 1 hour at 37°C to digest parent
amplification products to yield the partial 5-HT2A-TM4ΔNP construct. This chimera (TM4ΔNP)
had the effect of substituting the consecutive Phenylalanine and Leucine found in WT 5-HT 2A
with the consecutive Isoleucine and Methionine found in WT 5-HT 2C (Fig 3 & 4).
For the construct (5-HT2A-TM4ΔNF) involving a complete mutation of the residues that
lay in the half of TM4 closest to the N terminal of 5-HT 2A, a similar approach to creating the
partial chimera was used; however, the DNA template used before cycling was the 5TM4ΔNP
partial construct described above. The forward and reverse primers designed for the mutation as
follows (duplex forming nucleotides highlighted):
Forward: 5'GATATACCTACTGATATGGTCCAAACAATAGCGATTTTCATGATTGCCTTAGTTCTG
GAG-3'
Reverse: 5'TCCAGAACTAAGGCAATCATGAAAATCGCTATTGTTTGGACCATATCAGTAGGTATA
TC-3'
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The parameters for thermocycling were as follows: 1 cycle at 95°C followed by 18
cycles of 30 minutes at 95°C, 1 minute at 55°C and 7 minutes at 68°C. Similar to the partial
construct, Dpn1 restriction enzyme was used to digest the unmutated parent DNA. Ultimately
this produced the full N terminal half TM4 chimera 5-HT2A-TM4ΔNF by substituting the
consecutive Isoleucine and Alanine found in the 5-HT 2A-TM4ΔNP (and in WT 5-HT2A) with the
consecutive Alanine and Isoleucine found in 5-HT 2C respectively. (Fig 3 & 4).
Since all other residues located on the half of TM4 closest to the N terminal end of the
GPCR are the same when considering the aligned sequence of 5-HT 2A and 5-HT2C, the above
two constructs are sufficient to assess the hypothesis of the paper.
Purification, Amplification, and Sequencing of Constructs
Wild Type constructs obtained were transformed into XL1-Blue super competent cells
using the heat shock method and let to incubate overnight on Agar plates, before a single colony
was picked. This colony was let to grow on a shaker in LB broth at 37°C overnight before
purification and amplification by the protocol described in QIAGEN Plasmid Maxi Prep.
The products from the Site Directed Mutagenesis were transformed in a similar manner
described above; however, the selected colony was first amplified using QIAGEN Plasmid Mini
prep before being mixed with primer to be sent for sequencing. The primer used for sequencing
of both Mutant constructs (5-HT2A-TM4ΔNP & 5-HT2A-TM4ΔNF) was as follows.: 5’-AGC
TGA TAT GCT GCT GGG TT -3’. Following sequence verification, the constructs were
retransformed and plated overnight, a colony to grow in broth was selected, and a Maxi Prep to
amplify yield of the construct was conducted.
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Maintenance of HEK 293 Cells
Human Embryonic Kidney (HEK293) cells were used for transfection. These cells were
incubated in a cell culture environment with 5% humidified CO 2 at 37°C. The media selected to
maintain the cells, Dulbecco’s modified Eagle’s medium (DMEM), includes pH sentsitive
Phenol red and was further modified by the addition of dialyzed fetal bovine serum (dFBS) equal
to 10% of the total volume of media and Penstrep equal to 1% of the total media volume (except
immediately prior to transfection, as noted below). Cells were split routinely using fresh media in
a ratio between 1:12 and 1:8, to allow for growth and for fresh media, and never passaged higher
than 22 times.
Transfection of HEK 293 cells
Plates containing HEK 293 cells prepared for transfection or co-transfection were
aspirated of any media and replaced with DMEM containing only 10% dFBS but no Penstrep
prior to transfection (although reducing the chances of contamination, Penstrep inhibits
transfection.) Plasmid containing the desired construct was added to a vial of Gibco Opti-MEM
media before Invitrogen Lipofectamine 2000 reagent was added according to manufactures
instructions in a 1:2 protein to lipofectamine ratio in a separate vial of Gibco Opti-MEM media;
the mixtures were allowed to incubate separately for 1 hour. Following incubation, the mixtures
were combined and added to Penstrep free plates containing HEK 293 cells in DMEM (+10%
dFBS). Cells were grown to 80% confluency before transfection. Media containing
lipofectamine was removed 24 hours following transfection; cells were allowed a maximum of
48 hours after transfection before harvesting as described below.
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Using the method described above, transfections of single plasmids were done using 6μg
of DNA per plate (Ex:8 plates = 48μg of plasmids total) This corresponds to a lipofectamine
ratio of 12μg per plate or 96μg total. This includes the individual transfection of the constructs
HA-mGluR2-mCitrine, c-Myc-5-HT2A-mCherry, and c-Myc-5-HT 2A-TM4ΔNP-mCherry.
Considering co-transfection of the serotonin and glutamate GPCRs, the HA-mGluR2mCitrine plasmid and c-Myc-5-HT2A-mCherry plasmid were transfected in a ratio of 2:1 (For
example, 6μg of mGlu2 and 3μg of 5-HT2A for a total of 9μg DNA per plate to be combined with
18μg lipofectamine total). Co-transfection of the partial mutant c-Myc-5-HT 2A-TM4ΔNPmCherry with HA-mGluR2-mCitrine was performed using the same ratio. The full mutant cMyc-5-HT2A-TM4ΔNF-mCherry is yet to be transfected.
Preparation of Membrane from Cell Pellets
48 Hours following transfection, cells were harvested using calcium and magnesium free
DPBS (Dulbecco’s Phosphate Buffer Saline;) the buffer allows cells to dissociate from the plate
and be scraped into a falcon before centrifugation. The resulting cell pellets were frozen at
-80°C before being prepared into membranes.
For such preparations, cell pellets were resuspended in Tris-HCL buffer and
homogenized before centrifugation. Cell membrane isolation begins with Initial low speed
centrifugation of the homogenized solution at 1,000 xg in 4°C, which pellets heavier cell
organelles such as the nucleus. Centrifugation of the supernatant from the initial spin at high
speed (40,000 xg) results in a cell membrane precipitate which can be washed with Tris-HCL
and recentrifuged at the same speed. The resulting supernatant is thrown off leaving isolated cell
membranes containing the GPCR plasmids of interest in the precipitate.
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Co-Immunoprecipitation Studies
The initial co-immunoprecipitation was conducted using membrane preparations of cotransfected wild type HA-mGluR2-mCitrine and c-Myc-5-HT2A-mCherry containing 1mg
(1000μg) of protein. In this assay the prepared membrane samples were first exposed to RIPA
lysis buffer and then solubilized to allow the GPCRs within the membrane to become surrounded
by surfactant before being rotated with Protein A/G PLUS-Agarose immunoprecipitation beads.
For wildtype assays, anti-c-myc antibody (Cell Signaling, catalog #2276) in a 1:100
concentration was added to the beads mixture before overnight rotation at 4°C., Total Protein
controls were taken prior to antibody addition and immediately after overnight rotation
(supernatant from 14000RPM spin) before final solubilization of the immune complexes formed
by the assay.
Products of the Co-IP (precipitate from 14000RPM spin after overnight rotation) were
washed and resolubilized with buffer before being prepared for immunoblot analysis. An aliquot
of the final wash step was also reserved for Western Blot analysis to detect Co-IP signal that may
have been lost to the final wash steps.
Protein Estimation and Western blotting
In order to resolve equal amounts of protein in each lane during the SDS-PAGE process,
the protein composition of membrane preparations was estimated using the Bradford Protocol.
(Note that for co-transfected samples used in Co-IP experiments, protein composition was
estimated prior to the Co-IP.) A spectrophotometer set to a wavelength of 595nm detects the
blue-dye within reagent when bound to proteins. A standard curve was stablished by detecting
the absorbance of increasing control amounts of Bovine Serum Albumin (BSA). The curve was
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used to interpolate an estimated protein composition (in μg/μl) of the membrane preparations
from cells transfected with WT c-myc-5-HT2A and c-myc-5-HT2A-TM4ΔNP receptors.
Two immunoblot assays, one with the aim of analyzing the results of the Co-IP
experiment (Figure 3) and another blot to verify expression of the partial chimera 5-HT 2ATM4ΔNP (Figure 4) were conducted and shown in the Results & Discussion section.
Western blot following Co-Immunoprecipitation:
All samples were heated to 95 degrees at 5 minutes before loading onto a 12% polyacrylamide
gel. Lanes 1 and 2 with Total Protein and Total Protein Analog (supernatant described above)
respectively, were loaded with 20μl of sample and 5μl of Laemmli buffer each. Lane 3,
composed of sample from a late wash step, and Lane 4 containing the final Co-IP products were
loaded with the same specifications. The samples were let to resolve at 60V for 1 hour and then
100V for 3 hours before overnight transfer to a nitrocellulose membrane in the cold room (30V).
The membrane was blocked with buffer containing BSA, milk, and TBST to avoid nonspecific
binding before adding antibody. The membrane was incubated in a 1:1000 dilution of primary
antibody, HA-Rabbit Ab (Cell Signaling Catalog #2367), for 1 hour at room temperature. The
membrane was then washed, blocked, and incubated in secondary antibody, Anti-Rabbit
Horseradish peroxidase (HRP) conjugated Ab (Cell Signaling Catalog #7074) for 2 hours
(1:5000 dilution) at room temperature before being visualized with enhanced chemiluminescence
reagents (ThermoScientific) in accordance with manufacture instructions.
Western Blotting to Verify Expression of the Partial Chimera 5-HT 2A-TM4ΔNP
All samples were heated to 95 degrees for 5 minutes before loading onto a 12% polyacrylamide
gel. Both lanes of the gel were loaded with a volume equal to 20μg of protein by mixing the
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appropriate volume with 5μl of 5x Laemmli buffer and Tris-HCL up to a total sample volume of
25μl per lane. SDS-PAGE was conducted at 60V for 1 hour and 100V for 2.5 hours before being
transferred onto a nitrocellulose membrane overnight at 30V in 4°C. Following wash and
blocking steps, the membrane was incubated in primary antibody, c-Myc-Tag-Mouse Ab (Cell
Signaling, catalog #2276) for 1 hour (1:000 dilution) before being washed, blocked, and
incubated in Anti-Mouse Horseradish peroxidase (HRP) conjugated secondary Ab (Cell
Signaling, catalog #7076) in a 1:5000 dilution. Visualization of the immunoblot of the chimeric
construct was conducted using the same chemiluminescence reagents mentioned earlier.
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Results and Discussion
Prior studies suggested that TM4 of 5-HT2A is necessary for mediating heteromerization,
with this in mind, my study developed two mutant constructs 5-HT 2A-ΔTM4NP and 5-HT2AΔTM4NF, consisting of residues from 5-HT2C swapped into sections of the TM4 domain.
Although the chimeras are named “partial” and “full”, it is important to consider that they only
consider one half, (the N terminal half,) of TM4 with regards to nomenclature. The sequencing
results of both constructs are displayed in Figures 1 (next page) and suggest that the desired
mutations were made in the correct positions. Figure 1 highlights which portions of TM4 are
considered the N terminal half as opposed to the C terminal half.
The choice to design chimeric constructs mutated on the N terminal half of TM4 rather
than on the C terminal half was simply a matter of convenience. Figure 1 and 2 (displayed on
horizontal pages blow) clearly show the mutation of 2 sequential amino acids (FLIM)
followed by the mutation of 2 other sequential amino acids (IAAI); because the mutated
residues were sequential, they could each be created using a single site directed mutagenesis
protocol. Figure 2 also highlights the individual nucleotides which needed to be swapped for the
mutation to occur – notice in the orange box for example showing the partial chimeric construct
(FLIM) only three out of the six nucleotides required to form the two residues needed to be
swapped, while in the full TM4 chimera (IAAI) four out of 6 nucleotides needed to be
changed. To simplify the process of making mutations, I chose to begin with the N terminal half
of TM4. However, additional C terminal chimeras may need to be made in future studies, using
the same strategies shown in figures 1 and 2, if the full N terminal half TM4 chimera (5-HT 2AΔTM4NF) fails to break immunoprecipitation of the 5-HT 2A-mGlu2 complex.
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TM4 N terminal Half

Figure 1. Alignment of residues in Human 5-HT2A and 5-HT2C along with both partial (5-HT2A-TM4ΔNP) and full (5-HT2A-TM4ΔNF)
TM4 N terminal half mutants. The entire TM4 of 5-HT2A receptor is outlined in black. The N terminal half of the Transmembrane
domain is highlighted as the left box within the TM4 outline corresponding to A2064.42 through W2144.50. Sequence consensus of all
four constructs is displayed. The 5-HT2A-TM4ΔNP construct replaces the phenylalanine4.43 and leucine4.44 found in 5-HT2A with the
consecutive isoleucine4.44 and methionine4.55 found in WT 5-HT2C. The 5-HT2A-TM4ΔNF construct incudes the same residue changes
as 5-HT2A-TM4ΔNP with the following additions: the consecutive isoleucine4.47 and alanine4.48 found in 5-HT2A are substituted with
the consecutive alanine4.47 and isoleucine4.48 found in 5-HT2C. Notice that all other residues denoted as within the TM4 N terminal half
of 5-HT2A share homology with the 5-HT2C receptor so have not been mutated.
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Figure 2. Nucleotide Sequence alignment of Human 5-HT2A and 5-HT2C and both partial (5-HT2A-TM4ΔNP) and full (5-HT2ATM4ΔNF) TM4 N terminal half mutants. The black box denotes the half of TM4 closest to the N terminal of the GPCR. In the partial
(5-HT2A-TM4ΔNP) chimera, the TTT coding for Phenylalanine4.43 and CTG coding for Leucine4.44 from 5-HT2A were replaced with
ATC (Isoleucine4.43) and ATG (Methionine4.44) naturally found in 5-HT2C as shown in the orange box. The blue box highlights changes
made to produce the full (5-HT2A-TM4ΔNF) chimeric construct in addition to the residues mutated in 5-HT2A-TM4ΔNP: the ATT and
GCT coding for Isoleucine4.47 and Alanine4.48 respectively were substituted with GCT and ATT, matching the sequence of 5-HT2C.
Notice that some nucleotides in the figure appear to differ in mutant constructs than in 5-HT2C; it is important to note however that
multiple codons can code for the same amino acids (ex: GCA and GCC both code for Alanine while ATC and ATT both code for
Isoleucine. Thus, certain individual nitrogenous bases need not be mutated to achieve the sequence of residues desired for each
construct
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The coimmunoprecipitation experiment in this study was assessed by Western Blot
shown in Figure 3 and confirms results obtained in (Moreno 2012) suggesting that WT 5-HT 2A
and mGlu2 immunoprecipitated when co-transfected in HEK293 cells.
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Figure 3. Western blot probing for HA (tagged as HA-mglu2) following Coimmunoprecipitation
involving a c-Myc Antibody (tagged as c-Myc-5-HT 2A). Aliquots of sample before Co-IP antibody
was added (lane 1) and samples of supernatant after overnight Co-IP rotation but before final
wash or solubilization buffers were added (lane 2). Lane 1 and 2 are used as Total Protein
references. Lane 4 corresponds to sample yielded after completing the entire Co-IP protocol,
while Lane 3 includes sample from a late wash step which some Co-IP signal may have been lost
to. All four lanes probed for HA-mGlu2 with Primary Antibody: HA-Tag Rabbit Ab; Secondary
Antibody: Anti-Rabbit HRP Ab.
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Figure 3 shows that the Co-IP lane (lane 4) has 2 clear molecular weight bands at near
120 kDa and near 240 kDa which correspond to WT HA-mGluR2-mCitrine in its monomeric
and dimeric forms respectively (Maeso Group, unpublished). The wash step sample in lane 3
contains identical bands to those in lane 4; this is not surprising as the wash step sample was only
included to detect any Co-IP signal lost to the final wash steps in the protocol. Lane 1 and 2 are
total protein control lanes, meaning that signal in the Co-IP lane should not be present unless
also present in the Total Protein lanes 1 and 2; our results are congruent with this idea. Bands
displayed below 100 in the total protein lanes may be attributed to nonspecific binding which
was lost in the Co-IP and wash lanes after final solubilization steps.
To assess the hypothesis of the paper, the full chimeric construct (5-HT 2A-ΔTM4NF)
should first be coimmunoprecipitated with WT mGlu2. We can either expect the presence of a
Co-IP band or absence of a Co-IP band
If 5-HT2A-ΔTM4NF CAN coimmunoprecipitate with mGlu2 (band present)
There are multiple reasons for a result in which 5-HT 2A-ΔTM4NF and mGlu2 can
coimmunoprecipitate and display a band. It may be that N terminal half TM4 residues do not
mediate the heteromeric interface of 5-HT2A-mGlu2 complex. Or they may still show Co-IP
signal, but one that is weak in comparison to that of a full C terminal chimera which does not
disrupt coimmunoprecipitation at all. The best way to assess this result would be to create a 5HT2A chimera considering the full C terminus half of TM4 (for example: 5-HT 2A-ΔTM4CF) and
compare the coimmunoprecipitation results from both constructs. If the 5-HT 2A-ΔTM4NF
produces a band while the 5-HT2A-ΔTM4CF does not, then the residues responsible for
mediating heteromerization are located in the C terminal half of the TM4 in 5-HT 2A. However, if
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both constructs display a Co-IP signal, a quantification of the Co-IP signal is necessary. A
method similar to Moreno, 2012 in which coimmunoprecipitation of both N terminal and C
terminal half TM4 chimeric constructs of mGlu2 containing residues from mGlu3 both produced
Co-IP signal, can be followed: after running multiple experiments, the signals were aggregated
and quantified in terms of immunoreactivity. The same approach can be used with multiple
chimeras producing Co-IP signal. The chimera with the lowest immunoreactivity is likely to be
responsible for mediating the heteromeric interface of 5-HT 2A.
If 5-HT2A-ΔTM4NF can NOT coimmunoprecipitate (band absent):
This would validate the hypothesis of the experiment. A lack of Co-IP signal would
indicate that the heteromeric interface was broken when the N terminal half was mutated –
suggesting that one or more of original residues (phenylalanine 4.43; leucine4.44; alanine4.47;
isoleucine4.48) in the N terminal half of TM4 in 5-HT2A mediate complex formation. Co-IP of the
partial mutant could be used to assess which set of residues FL or IA is more responsible;
however, a Co-IP experiment does not differentiate direct interaction of proteins from indirect
interaction via additional scaffolding proteins. Additional approaches such as crosslinking
photoreactive unnatural amino acids to identify the individual residues responsible, as described
further in the future directions section can be used,

31

250kD
150
100
75
50
37

Wild Type 5HT2A

Anti-c-mycMouse Ab

Partial Chimera
(5-HT2AΔTM4NP)

WB

Figure 4. Characterization of Partial TM4 Mutation with Western Blot probing for c-myc-5HT2A; Ladder merged for Clarity. Lane one samples were previously transfected with WT 5-HT 2A
receptor. Lane two was loaded with sample previously transfected with the partial mutant (5HT2A-ΔTM4NP). Primary Antibody: Myc-Mouse Ab. Secondary Antibody: Anti-Mouse Ab.
Finally, figure 4 attempts to characterize the mutant receptor by immunoblot assay. If the
mutant is expressed properly, we would expect bands of similar molecular weight for both
mutant and wild type receptors. While the immunoblots do not indicate a 53kDa band expected
by a monomeric 5-HT2A receptor, one must account for the weight of c-myc (41kDa) and mcherry tags on 5-HT2A (29kDa) in addition to the possibility of the receptor dimerizing or
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oligomerizing. In any case, since the mutant plasmids must be translated by the cell without
misfolding or being degraded, the homology of the bands indicated on the western blot suggest
that the 5-HT2A-ΔTM4NP chimeric receptor was properly expressed in a manner similar to WT
5-HT2A. The purpose of selecting the partial chimera 5-HT 2A-ΔTM4NP in Figure 4 was to ensure
that the partial chimera displayed molecular weight bands similar to that of wild type receptors,
before creating the full N terminal TM4 chimera 5-HT2A-ΔTM4NF. The full construct and any
additional C terminal 5-HT2A chimeras can also be characterized by immunoblot.
There are several additional ways to characterize the mutant receptors in future studies
and ensure structural and functional similarity to wild type receptors. To assess whether the
mutant receptors bind to ligands in a manner similar to WT 5-HT 2A, radioactive Ketanserin
binding experiments as outlined in Moreno, 2016 could be conducted. We would expect similar
displacement curves for individually transfected mutant and wild type receptors. The binding
between curves of co-transfected wild type receptors and co-transfected mutant 5-HT 2A chimeras
with mGlu2 should slightly vary depending on the mutation in the chimera. Additionally,
experiments considering the cross talk between the protomers of the complex, using LY379268,
(an mGlu2 agonist) as described in (Moreno 2016) could be conducted. We would only expect
downstream 5-HT2A Gq/11 calcium signaling in mutant chimeras which are not responsible for
breaking the binding interface. Finally, to assess the proper localization of the protein following
translation, Immunocytochemistry experiments as those described in Gonzalez-Maeso, 2008 can
be conducted. We would expect a distribution of mutant receptors similar to that of wild type
receptors. Mutant receptors could also be co-transfected with mGlu2 before comparing their
immunocytochemistry results to those of WT co-transfection.
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Conclusions and Future Directions
Findings:
1. Immunoblot experiments conducted in this study are congruent with previous findings
that wild type mGlu2 and 5-HT2A coimmunoprecipitate
2. Mutant constructs (5-HT2A-ΔTM4NP and 5-HT2A-ΔTM4NF) created in this study can
assess the hypothesis of the paper using the same methods for Co-IP.
a. Multiple Co-IP signals can be discriminated by quantification
b. Additional chimeric constructs involving the C terminal half of 5-HT 2A/C can be
made (ex: 5-HT2A-ΔTM4C-P/F) to assess their role in heteromerization.
3. Expression of the partial mutant is verified by similar immunoblot bands displayed for
WT 5-HT2A and 5-HT2A-ΔTM4NP western blot.
4. Additional characterization of any constructs produced by this study or those created in
the future may include:
a. Immunocytochemistry
b. [H3] Ketanserin Binding
c. Crosstalk experiments (Calcium Assay)
Future Directions if the 5-HT2A N terminal half of TM4 is determined to mediate the
heteromeric interface: Photo-Crosslinking Approach
If no co-immunoprecipitation between 5-HT2A-ΔTM4NF and mGlu2 is observed, a photocrosslinking approach similar to Grunbeck, 2011 & Valentin-Hansen, 2014, mentioned earlier,
could be used to identify individual amino acids involved in the interface. Recall that while
coimmunoprecipitation offers valuable information on the sections of the TM4 involved in
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heteromerization, it does not offer evidence for a direct interaction between individual amino
acids. Although traditional cysteine cross linking experiments such as ones used to identify a
homomeric dopamine receptor (Han. 2009) can be used to assess a direct interaction, the
presence of endogenous cystines mediating the Venus Fly Trap domains of mGlu2 presents a
problem; although these cystines can be mutated to serine or alanine, this substitution seems to
alter the structure and dynamics of the mGlu2 homodimer (Koehl, 2019.) While the technical cotransfection of multiple plasmids required by a photo-crosslinking approach may take additional
optimization, the approach taken by Maeso Group, Unpublished to identify individual amino
acids responsible in the mGlu2 receptor, could be modeled to identify the individual residues of
5-HT2A responsible for complex formation without compromising the overall structural integrity
of either protomer in the complex.
If the N terminal end residues of TM4 in the 5-HT 2A are found to be implicated in the
dimeric interface, that is, if coimmunoprecipitation of the mGlu2 and 5-HT 2A-ΔTM4NF fails to
occur, four separate constructs would need to be created to perform a photo cross linking assay.
The four new constructs correspond to the four residues mutated (phenylalanine 4.43; leucine4.44;
alanine4.47; isoleucine4.48) to create the 5-HT2A-ΔTM4NF construct. The “cocktail” of plasmids
transfected, would be refined to introduce a single photoreactive unnatural amino acid
corresponding to phenylalanine4.43, leucine4.44, alanine4.47, or isoleucine4.48 in each of the four new
constructs respectively. These constructs could undergo UV mediated crosslinking, which would
reveal whether one or more of the four original amino acids mutated in 5-HT 2A form a direct
interaction with mGlu2 and participate directly in establishing the heteromeric interface of the
5-HT2A-mGlu2 complex.
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The implication of the mGlu2-5-HT2A complex in schizophrenia is clear. The results
produced in this study offer valuable constructs to be included in designing future studies. With
the mutant constructs created, Co-IP assays can be conducted with the same methods to identify
if either disrupts the binding of 5-HT2A-mGlu2. If so, future photo-crosslinking studies can focus
on identifying individual amino acids within 5HT 2A responsible for the heteromeric interface. If
not, additional C terminal TM4 chimeras of the 5-HT2A with aligned residues from 5-HT2C will
need to be constructed, coprecipitated, and immunoassayed before verifying the role of the C
terminal residues. In any case, gaining a more complete structural understanding of the mGlu2-5HT2A will be beneficial for therapeutic strategies in Schizophrenia.
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